34 results about "Intrinsic factor" patented technology

Improved delivery of zinc using haptocorrin or intrinsic factor modified to include a zinc binding sequence that can outcompete dietary zinc inhibitors such as phytin. Known zinc binding sequences can be assayed to determine competitiveness with respect to phytin and, if successful, incorporated into the B12 binding site of haptocorrin or intrinsic factor. Thus a method of producing functional human haptocorrin or intrinsic factor which binds to zinc includes the steps of modifying human TCN1 or GIF to comprise one or more zinc-binding site sequences, constructing a vector containing the modified human TCN1 or GIF sequence, and introducing the vector into a host cell for a time and under conditions sufficient for expression of the functional human haptocorrin or intrinsic factor. The resulting zinc binding complex can be orally administered to zinc deficient individuals to improve the amount of dietary zinc available to the individuals.

The invention relates to a radio frequency identification-based electronic tag motion direction judgment method and system. The method includes the following steps that: when radio frequency antennas detect electronic tags, echo phases read by the radio frequency antennas are obtained, wherein at least two radio frequency antennas are adopted; the differences of adjacent echo phase values read by each radio frequency antenna are calculated; and the moving directions of the electronic tags can be judged according to the plus-minus signs of the differences of the adjacent echo phase values read by each radio frequency antenna. According to the technical schemes provided by the invention, the echo phases of the electronic tags are adopted as main parameters for direction judgment, error brought by factors such as environmental interference and multipath effects can be decreased from the data source; judgment is carried out by using the plus-minus signs of the echo phase differences, and therefore, influence caused by an intrinsic factor of phase cycle ambiguity can be eliminated, and judgment of the movement direction of the tags is more accurate; the calculation of the echo phase differences, and the judgment of the movement direction of the tags are low in complexity, and the timeliness of the judgment of the movement direction of the electronic tags is higher.

The invention provides bullacta exarata health-care fine dried noodles and a preparation method of the bullacta exarata health-care fine dried noodles. The fine dried noodles comprise the following raw materials in percentage by weight: 65-85 percent of flour, 5-15 percent of bullacta exarata protein powder, 3-10 percent of artemisia songarica schrenk seed powder, 2.5-5 percent of celery seeds and 2.5-5 percent of rorippa indica seeds, wherein the raw materials are uniformly mixed to be prepared into a dough, and the dough is aged, pressed and cut into noodles; the noodles have fine and smooth mouthfeel, and are aromatic, mellow and delicious. The original flavor and the bioactive constituents of the bullacta exarata are remained at a full rate and are not lost; the problems that the bullacta exarata has fishy smell and the eating environment and the eating mode are limited are solved; a new approach for deep processing of the bullacta exarata is developed. The boiling fastness of the noodles is increased, the toughness is improved, the strength is high, the noodles do not break, the soup does not become milky, the intrinsic factors for high probability of deterioration are reduced, and the guarantee period is greatly prolonged. The noodles have complete and rich nutrients and a prominent health-care function and enable a better digestive absorption function. The immunity can be enhanced and various focuses of the human bodies can be eliminated after a person frequently eats the noodles, so that the effects of building the body and prolonging the life are achieved.

Methods are described for the development of monoclonal antibodies to intrinsic factor and the application of said antibodies in the development of B12 immunoassays. In particular, antibodies are described that are capable of binding to intrinsic factor only in the absence of vitamin B12, and that are released from binding in the presence, and upon the binding, of vitamin B12 to intrinsic factor. Assays may be formatted such that either antibody or intrinsic factor is immobilized or labeled.

The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.